Intellia Therapeutics: Wells Fargo Sees 173% Growth Potential!

Intellia Therapeutics (NTLA) has made it to the list of the analysts' top 10 price targets. The biotech company has captured significant attention in recent years, particularly due to its groundbreaking advancements in CRISPR gene editing. This technology allows for precise modifications to the genetic material of organisms. For investors, it's crucial to understand the application areas and potential of this technology, as it forms the foundation for the company's product pipeline. Current product pipeline overview Intellia's product pipeline...